Anavex Life Sciences Corp (AVXL)

[drv17]

Axovant Launches Arvelle Therapeutics to Commercialize Epilepsy Drug
Published: Feb 14, 2019 By Mark Terry

I might have missed this but I don't recall seeing anything on the board about this.

Arvelle is launching by licensing European rights to cenobamate from SK Bio-Pharmaceuticals. This is a novel investigational anti-epileptic drug for the treatment of partial-onset seizures. Axovant takes a 5 percent preferred equity stake in Arvelle after the initial planned capital raise of more than $100 million from a global syndicate of investors.

In November 2018, SK Biopharmaceuticals filed a new drug application (NDA) with the U.S. Food and Drug Administration (FDA), which was accepted in February 2019. It has a target action date of November 21, 2019. Arvelle expects to file a Marketing Authorization Application (MAA) based on data that came out of SK Biopharmaceutical’s development program.

Two of Axovant’s programs are nelotanserin, a highly selective inverse agonist of the 5HT2A receptor, and RVT-104, an early-stage asset. Nelotanserin is being evaluated in patients with Dementia with Lewy bodies (DLB) or Parkinson’s Disease Dementia (PDD) who are experiencing REM sleep behavior disorder (RBD). RVT-104 is a proposed combination of a higher than presently approved dose of cholinesterase inhibitor rivastigmine and a peripherally active muscarinic receptor antagonist. It is being studied as a possible treatment for Alzheimer’s disease and dementia with Lewy bodies.

I hope some of you knowledgeable posters comment on this for those off us that do not have the scientific background. TIA